0001493152-23-034856.txt : 20230929 0001493152-23-034856.hdr.sgml : 20230929 20230929163027 ACCESSION NUMBER: 0001493152-23-034856 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230927 FILED AS OF DATE: 20230929 DATE AS OF CHANGE: 20230929 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Alvino Mark CENTRAL INDEX KEY: 0001356828 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15771 FILM NUMBER: 231296160 MAIL ADDRESS: STREET 1: C/O SCO SECURITIES LLC STREET 2: 1285 AVENUE OF THE AMERICAS 35TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ABEONA THERAPEUTICS INC. CENTRAL INDEX KEY: 0000318306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 830221517 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6555 CARNEGIE AVE, 4TH FLOOR CITY: CLEVELAND STATE: OH ZIP: 44103 BUSINESS PHONE: 646-813-4701 MAIL ADDRESS: STREET 1: 6555 CARNEGIE AVE, 4TH FLOOR CITY: CLEVELAND STATE: OH ZIP: 44103 FORMER COMPANY: FORMER CONFORMED NAME: PLASMATECH BIOPHARMACEUTICALS INC DATE OF NAME CHANGE: 20140922 FORMER COMPANY: FORMER CONFORMED NAME: ACCESS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960209 FORMER COMPANY: FORMER CONFORMED NAME: CHEMEX PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 4 1 ownership.xml X0508 4 2023-09-27 0 0000318306 ABEONA THERAPEUTICS INC. ABEO 0001356828 Alvino Mark 6555 CARNEGIE AVE., 4TH FLOOR CLEVELAND OH 44103 1 0 0 0 0 Common Stock 2023-09-27 4 S 0 6316 3.9145 D 69900 D The sale reported in this Form 4 was to cover tax obligations associated with vesting of restricted stock awards. Weighted average price. These shares were sold in multiple transactions at prices ranging from $3.8200 to $4.2050 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. /s/ Mark Alvino 2023-09-29